Risk assessment and primary VTE prevention in the cancer patient

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue SUPPL. 1, 2003, Pages 36-41

  Levine, Mark N ^a   Lee, Agnes Y Y ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLEEDING; CANCER PATIENT; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; GENERAL SURGERY; GYNECOLOGIC SURGERY; HIGH RISK PATIENT; HUMAN; INJECTION; LOW DRUG DOSE; META ANALYSIS; NEUROSURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL PATIENT; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0345359891     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073288     Document Type: Conference Paper

References (45)

1. Kakkar AK, Williamson RC: Prevention of venous thromboembolism in cancer patients. Semin Thromb Haemost 1999;25:239-243.
2. Gallus AS: Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 1997;78:126-132.
3. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB: Deep vein thrombosis of the leg: Is there a 'high risk' group? Am J Surg 1970;120:527-530.
4. Agnelli G, Radicchia S, Nenci GG: Diagnosis of deep vein thrombosis in asymptomatic high-risk patients. Haemostasis 1995;25:40-48.
5. 125I-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost 1989;62:830-834.
6. 125I-fibrinogen leg scanning: Reassessment of its role for the diagnosis of venous thrombosis in post-operative patients. Thromb Haemost 1993;69:2-7.
7. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: An international multicentre trial. Lancet 1975;2:45-51.
8. Rahr HB, Sorensen JV: Venous thromboembolism and cancer. Blood Coagul Fibrinolysis 1992;3:451-460.
9. Palmer AJ, Schramm W, Kirchhof B, Bergemann R: Low molecular weight heparin and unfractionated heparin for prevention of thromboembolism in general surgery: A meta-analysis of randomised clinical trials. Haemostasis 1997;27:65-74.
10. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N: Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analyses. Br J Surg 1997;84:750-759.
11. Nurmohamed MT, Rosendaal FR, Buller HR, et al: Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 1992;340:152-156.
12. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP: Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992;305:913-920.
13. Bergqvist D, Burmark US, Flordal PA, et al: Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995;82:496-501.
14. Koppenhagen K, Adolf J, Matthes M, et al: Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 1992;67:627-630.
15. The European Fraxiparin Study (EFS) Group: Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988;75:1058-1063.
16. Kakkar VV, Cohen AT, Edmonson RA, et al: Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993;341:259-265.
17. Nurmohamed MT, Verhaeghe R, Haas S, et al: A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995;169:567-571.
18. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H: Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Sur 2001; 88:913-930.
19. ENOXACAN Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double blind randomized multi-centre trial with venographic assessment. Br J Surg 1997;84:1099-1103.
20. Eldor A, Bergqvist D, Agnelli G, et al: Prolonged thromboprophylaxis in patients undergoing abdominal cancer surgery with enoxaparin: The Enoxacan II Study (abstract). Blood 2000;98:706a.
21. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980.
22. Wells PS, Lensing AW, Hirsh J: Graduated compression stockings in the prevention of postoperative venous thromboembolism: A meta-analysis. Arch Intern Med 1994;154:67-72.
23. Roberts VC, Cotton LT: Prevention of postoperative deep vein thrombosis in patients with malignant disease. Br Med J 1974;1:358-360.
24. Allan A, Williams JT, Bolton JP, Le Quesne LP: The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br J Surg 1983;70:172-174.
25. Clagett GP, Reisch JS: Prevention of venous thromboembolism in general surgical patients: Results of meta-analysis. Ann Surg 1988;208:227-240.
26. Cisek LJ, Walsh PC: Thromboembolic complications following radical retropubic prostatectomy: Influence of external sequential pneumatic compression devices. Urology 1993;42:406-408.
27. Hamilton MG, Hull RD, Pineo GF: Venous thromboembolism in neurosurgery and neurology patients: A review. Neurosurgery 1994;34: 280-296.
28. Clagett GP, Anderson FA Jr, Geerts W, et al: Prevention of venous thromboembolism. Chest 1998;114:531S-560S.
29. Nurmohamed MT, van Riel AM, Henkens CM, et al: Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996;75:233-238.
30. Agnelli G, Piovella F, Buoncristiani P et al: Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339:80-85.
31. Dickinson LD, Miller LD, Patel CP, Gupta SK: Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998;43:1074-1081.
32. Geerts WH, Heit JA, Clagett GP et al: Prevention of venous thromboembolism. Chest 2001;119:132S-175S.
33. Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM: Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: Report of a randomized controlled trial. Gynecol Oncol 1984;18:226-232.
34. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT: Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984;63:92-98.
35. Clarke-Pearson DL, Synan IS, Creasman WT: Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obstet Gynecol 1983;147:369-375.
36. Clarke-Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE: A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990;75:684-689.
37. Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, et al: Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988;18(6):561-567.
38. Heilmann L, von Tempelhoff GF, Kirkpatrick C, Schneider DM, Hommel G, Pollow K: Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: Efficacy, safety, and follow-up. Clin Appl Thromb Hemost 1998;4:268-273.
39. Levine M, Hirsh J, Gent M, et al: Double blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-889.
40. Samama MM, Cohen AT, Darmon JY et al: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
41. Bona RD: Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Haemost 1999;25:147-155.
42. Bern MM, Lokich JJ, Wallach SR, et al: Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial. Ann Intern Med 1990;112:423-428.
43. Couban S, Goodyear M, Burnell M, Dolan S: A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer (abstract). Blood 2002;100(11):2769.
44. Monreal M, Alastrue A, Rull M, et al: Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996;75:251-253.
45. Reichart P, Kretzschmar A, Biakhov M, Irwin D: A Phase III double blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, fragmin) in preventing catheter-related complications in cancer patients with central venous catheters (abstract). Proc Ann Meet Am Soc Clin Oncol 2002;21:1474.